myTomorrows is a Dutch startup that wants to disrupt the way patients with unmet medical needs access to development-stage treatments — drugs that are still undergoing clinical trials and working there way through a lengthy regulatory approval process. It targets patients who are typically up against time (e.g. specific types of cancer) and for whom drugs that could prolong or improve their quality of life do sometimes exist but aren’t yet “approved” and readily available on the market, even though positive trials have been conducted. Right now, how a patient accesses these treatments is somewhat of a lottery, if they can access them at all. By providing a platform that connects patients, doctors and drugs companies, myTomorrows wants to change that.
Today the company has announced a new funding round: it’s raised an additional $2.2 million from “friends and family”, adding to the $3.8 million previously raised from myTomorrows president…
View original post 258 more words